8-K: Sera Prognostics Reports Promising PRIME Study Results and Secures Funding for Expansion

Sera Prognostics announces positive results from its PRIME study, demonstrating significant reductions in neonatal morbidity and mortality, and secures $57.5 million in funding to expand commercial efforts and pursue FDA approval.

Summary

• Sera Prognostics announced its financial results for the fourth quarter and full year ended December 31, 2024.
• The company's PRIME study showed a 25% reduction in neonatal morbidity and mortality index (NMI) and an 18% reduction in neonatal length of hospital stay among the pre-specified modified intent-to-treat population.
• A broader intent-to-treat population showed a 20% reduction in NMI and 22% reduction in NICU admissions.
• In February 2025, Sera raised $57.5 million through a public follow-on offering, extending its cash runway through 2028.
• Fourth quarter 2024 revenue was $24,000, compared to $41,000 for the same period in 2023.
• Total operating expenses for the fourth quarter of 2024 were $9.4 million, a 6% increase from $8.9 million in the fourth quarter of 2023.
• The net loss for the quarter was $8.6 million, compared to $7.9 million for the prior-year quarter.
• Full year 2024 revenue was $77,000, compared to $306,000 for full year 2023.
• Total operating expenses for 2024 were $36.7 million, down from $40.1 million for 2023.
• The net loss for 2024 was $32.9 million, down from $36.2 million for 2023.
• As of December 31, 2024, the company had $68.2 million in cash, cash equivalents, and available-for-sale securities.

Sentiment

Score: 7

Explanation: The document presents a mixed picture. While the PRIME study results and the successful fundraise are positive, the declining revenue and continued net losses temper the overall sentiment. The company's strategic plans and potential for growth contribute to a moderately positive outlook.

Positives

• The PRIME study showed significant reductions in neonatal morbidity and mortality.
• The company successfully raised $57.5 million, extending its cash runway.
• Operating expenses decreased year-over-year.
• Net loss decreased year-over-year.

Negatives

• Revenue decreased in both the fourth quarter and full year 2024 compared to the previous year.
• The company continues to operate at a net loss.

Risks

• The company's future success depends on broad scientific and market acceptance of the PreTRM Test.
• The company relies on a concentrated number of material customers.
• The company may need to raise more capital in the future.
• Changes in FDA regulation of laboratory-developed tests could impact the company.

Future Outlook

Sera Prognostics plans to expand its commercial efforts in selected US geographies, partner with payers and providers, accelerate preparations for EU expansion, and fund additional studies to increase adoption, including a potential FDA submission.

Management Comments

• We are pleased with our progress during the year and, more recently, with the results of our full PRIME study, said Zhenya Lindgardt, President and CEO of Sera Prognostics.
• We are also thankful to our investors for supporting our fundraise last month, which we believe will promote our mission to mitigate the societal and healthcare costs of spontaneous premature birth and afford better outcomes for moms and babies by helping us drive adoption of our technology.

Industry Context

Sera Prognostics operates in the maternal and neonatal health diagnostics market, focusing on the prediction of preterm birth risk. Competitors may include companies offering similar diagnostic tests or those focused on improving pregnancy outcomes through other means.

Comparison to Industry Standards

• It is difficult to compare Sera Prognostics directly to industry standards due to the unique nature of its PreTRM test and its focus on preterm birth prediction.
• Other diagnostic companies in the maternal health space, such as Myriad Genetics (now Labcorp), offer prenatal screening tests, but these tests focus on different aspects of pregnancy health.
• The PRIME study results, showing a 25% reduction in neonatal morbidity and mortality, are a significant achievement and could position Sera Prognostics as a leader in preterm birth risk assessment.

Stakeholder Impact

• Shareholders benefit from the extended cash runway and potential for future growth.
• Patients and doctors benefit from the improved accuracy and availability of the PreTRM test.
• Employees benefit from the company's continued operations and expansion plans.

Next Steps

• Expand commercial efforts in selected US geographies.
• Partner with selected payers and providers to drive adoption of the PreTRM test.
• Accelerate preparations for expansion in the European Union.
• Fund additional studies designed to further increase adoption.
• Pursue a potential submission to the U.S. FDA seeking broad approval of the PreTRM test.

Key Dates

Keywords

PreTRM Test, preterm birth, Sera Prognostics, PRIME study, financial results, maternal health, neonatal health, biomarker, diagnostics